ArticleProstate cancer and prostatic diseases2015
Multiparametric MRI for detection of radiorecurrent prostate cancer: added value of apparent diffusion coefficient maps and dynamic contrast-enhanced images.
Article in Prostate cancer and prostatic diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Functional Magnetic Resonance Imaging in the Diagnosis of Locally Recurrent Prostate Cancer: Are All Pulse Sequences Helpful?Korean journal of radiologyPooled it
- The diagnostic value of mpMRI and PSMA-targeted PET/CT in radiorecurrent prostate cancer: a narrative review.Frontiers in oncology · 2026Review
- The Contemporary Role of Salvage Radical Prostatectomy in the Management of Recurrent Prostate Cancer: An Up-to-Date Review.Life (Basel, Switzerland) · 2024Review
- Evaluation of a Deep Learning-based Algorithm for Post-Radiotherapy Prostate Cancer Local Recurrence Detection Using Biparametric MRI.European journal of radiology · 2023Article
- Abbreviated MR Protocols in Prostate MRI.Life (Basel, Switzerland) · 2022Review
- Article
- Detection and staging of radio-recurrent prostate cancer using multiparametric MRI.The British journal of radiology · 2021Article
- Lesion-to-background ratio threshold value of SUVmax of simultaneous [Insights into imaging · 2020Article
- How Fast Can We Go: Abbreviated Prostate MR Protocols.Current urology reports · 2020Review
- Single-fraction image-guided robotic radiosurgery efficiently controls local prostate cancer recurrence after radical prostatectomy.BJUI compass · 2020Article
- Article
- Review
- Stereotactic prostate focal reirradiation therapy for local recurrence: preliminary results of Hartmann Oncology Radiotherapy Group.BJR open · 2019Article
- Multiparametric MRI for Suspected Recurrent Prostate Cancer after HIFU:Is DCE still needed?European radiology · 2018Article
- Two-years Postradiotherapy Biopsies: Lessons from MRC RT01 Trial.European urology · 2018Article
- Prostate MR Imaging for Posttreatment Evaluation and Recurrence.Radiologic clinics of North America · 2018Review
- The value of multimodality imaging in the investigation of a PSA recurrence after radical prostatectomy in the Irish hospital setting.Irish journal of medical science · 2018Article
- Can pre- and postoperative magnetic resonance imaging predict recurrence-free survival after whole-gland high-intensity focused ablation for prostate cancer?European radiology · 2017Article
- Evaluation of Prostate Cancer with PET/MRI.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2016Review
- Multiparametric Magnetic Resonance Imaging of Recurrent Prostate Cancer.Topics in magnetic resonance imaging : TMRI · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundMultiparametric magnetic resonance imaging (mp-MRI) is increasingly advocated for prostate cancer detection. There are limited reports of its use in the setting of radiorecurrent disease. Our aim was to assess mp-MRI for detection of radiorecurrent prostate cancer and examine the added value of its functional sequences.
methodsThirty-seven men with mean age of 69.7 (interquartile range, 66-74) with biochemical failure after external beam radiotherapy underwent mp-MRI (T2-weighted, high b-value, multi-b-value apparent diffusion coefficient (ADC) and dynamic contrast-enhanced (DCE) imaging); then transperineal systematic template prostate mapping (TPM) biopsy. Using a locked sequential read paradigm (with the sequence order above), two experienced radiologists independently reported mp-MRI studies using score 1-5. Radiologist scores were matched with TPM histopathology at the hemigland level (n=74). Accuracy statistics were derived for each reader. Interobserver agreement was evaluated using kappa statistics.
resultsReceiver-operator characteristic area under curve (AUC) for readers 1 and 2 increased from 0.67 (95% confidence interval (CI), 0.55-0.80) to 0.80 (95% CI, 0.69-0.91) and from 0.67 (95% CI, 0.55-0.80) to 0.84 (95% CI, 0.76-0.93), respectively, between T2-weighted imaging alone and full mp-MRI reads. Addition of ADC maps and DCE imaging to the examination did not significantly improve AUC for either reader (P=0.08 and 0.47 after adding ADC, P=0.90 and 0.27 after adding DCE imaging) compared with T2+high b-value review. Inter-reader agreement increased from k=0.39 to k=0.65 between T2 and full mp-MRI review.
conclusionsmp-MRI can detect radiorecurrent prostate cancer. The optimal examination included T2-weighted imaging and high b-value DWI; adding ADC maps and DCE imaging did not significantly improve the diagnostic accuracy.
Indexed as
Identifiers
25644248What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.